Home – Page 13 – The Cancer Letter

Issue 4 - Jan 24, 2020

TCL46-04 (324 downloads)

Report describes offshore accounts held by Moffitt scientists involved in China’s Thousand Talents program
Lawyer for former director Thomas Sellers says it’s “nonsense,” prepares defamation suit
What’s happening at H. Lee Moffitt Cancer Center?
Moffitt’s internal investigation: Scientists did not disclose funding from state-sponsored programs in China
On Jan. 17, Moffitt Cancer Center officials delivered the final report of the institution’s internal investigation to the Florida legislature, alleging that top leaders and researchers at the cancer center had opened personal bank accounts in China and received unreported personal payments and other research support.
Conversation with The Cancer Letter
Attorney: Moffitt has made a “very irresponsible decision”—Thomas Sellers “never was a participant” in China’s Thousand Talents Program
Contrary to declarations by Moffitt Cancer Center, Thomas Sellers, the institution’s ousted director, was not involved in the Thousand Talents program sponsored by the People’s Republic of China, said a Florida attorney who represents Sellers in preparing a lawsuit against the cancer center.
The price of smoking for a lifetime is lowest in the South, highest in the Northeast
Here are the numbers
A study evaluating the real cost of smoking by state over a lifetime ranked each of the states, finding that over an average lifetime smokers spend about $1 million to $2 million on tobacco-related costs, depending on the state they live in.
In Brief
- Oliver Bogler named director of NCI Center for Cancer Training
- University of Maryland joins Big Ten Cancer Research Consortium
- Victor Dzau elected NAM president for second term, Carlos del Rio named next foreign secretary
- Bert Vogelstein receives NAS Jessie Stevenson Kovalenko Medal
- Miami Cancer Institute launches inaugural Summit of the Americas
- Huntington, Park, Mounligan, Sanft receive new appointments at Yale Smilow Cancer Hospital
- City of Hope opens Orange County location as first phase of $1B expansion
- SU2C to announce health equity initiative to increase diversity in clinical trials
- Roxanne Taylor named chief marketing and communications officer at MSK
Clinical Roundup
- Surufatinib phase III study reaches primary endpoint in advanced pancreatic neuroendocrine tumors in China, trial to end early
- Pain control strategy reduces need for opioids in patients with head and neck cancer
- 9/11 responders have increased overall cancer incidence in thyroid, prostate, and leukemia cancers, study finds
Drugs & Targets
- FDA grants Tazverik accelerated approval as first treatment option for epithelioid sarcoma
- FDA grants priority review of belantamab mafodotin for relapsed or refractory multiple myeloma
- Myriad submits sPMA for BRACAnalysis CDx as companion diagnostic for Lynparza in metastatic castration-resistant prostate cancer
- Evotec, Indivumed collaborate on treatment for NSCLC
- Health Canada approves Keytruda + Inlyta for advanced RCC

Issue 3 - Jan 17, 2020

TCL46-03 (482 downloads)

Conversation with The Cancer Letter
Robert Winn holds forth on big data, bench-to-community research—and being the only African American director of an NCI-designated cancer center
Consider these data points on cancer disparities:
- The number of NCI-designated cancer centers: 71
- The number of African American directors of NCI-designated cancer centers: 1
Now meet Robert A. Winn, a pulmonologist who started his job as director of Virginia Commonwealth University Massey Cancer Center last month.
NCI increases funding for extramural research by $210M in FY2020; funds more than 125 additional competing awards
With a budgetary increase of $297 million in FY2020, NCI anticipates funding more than 125 additional competing awards over FY19 levels—and devoting more than $210 million in new funding to support extramural research and training opportunities.
Turman named president of ACT for NIH, group credited with boosting research funding
Richard Turman was named president on ACT for NIH, a Washington group that has played a key role in increasing federal appropriations for biomedical research over the past six years.
In Brief
- Al Benson named to new role in ECOG-ACRIN leadership
- Karen Reckamp to head medical oncology at Cedars-Sinai
- Dolores Hambardzumyan joins neurosurgery faculty at Mount Sinai
- Douglas Hanahan, Ping-Chih Ho receive appointments at Ludwig Cancer Research
- Northwell acquires Queens medical oncology practice
Clinical Roundup
- Multimodal genomic analyses predict response to immunotherapy in NSCLC
- Nanoparticle therapy offers potential new treatment for aggressive breast cancer
- MEAL study: eating more veggies, fruits will not cure, stop prostate cancer
Drugs & Targets
- FDA grants Rubraca Priority Review for advanced prostate cancer
- FDA accepts BLA for Priority Review of Opdivo + Yervoy in first-line NSCLC
- Concerto HealthAI collaborates with Pfizer, Janssen; launches eurekaHealth 3.0
- Roche, Illumina collaborate to broaden patient access to genomic testing
- Qiagen, Amgen collaborate on companion diagnostic development in NSCLC
NCI Trials
NCI Trials for Jan. 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 2 - Jan 10, 2020

TCL46-02 (438 downloads)

Guest Editorial
Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall
As I look through just-published tables of age-adjusted cancer mortality, I recognize an unprecedented development:
Immunotherapy is showing such a dramatic impact in the treatment of locally advanced and advanced non-small cell lung cancer that this effect elevates the statistics for all lung cancer and—this I find astonishing—you can even see its effect in age-adjusted cancer mortality overall.
Annals corrects NutriRECS red, processed meat papers to reflect industry-related funding from Texas A&M AgriLife
The Annals of Internal Medicine has published a correction to the controversial meta-analyses of health outcomes related to consumption of red and processed meat—announcing that the lead author of the journal’s “new guidelines,” Bradley Johnston, didn’t disclose funding from AgriLife Research.
Top 25 Stories of 2019
We went through our analytics: here is what your colleagues in oncology read in 2019.
NCI advisors approve seven concepts at joint NCAB/BSA meeting
The NCI Board of Scientific Advisors has approved seven new and reissue concepts—Requests for Applications, Requests for Proposals, and PARs.
In Brief
- Thomas J. Lynch Jr. named president and director of Fred Hutch
- Aaron Crane named executive VP of Seattle Cancer Care Alliance
- Bhramar Mukherjee, Christopher Friese named associate directors at Rogel Cancer Center
- Christopher Ballas appointed SVP at Innovative Cellular Therapeutics
Funding Opportunities
ALK Positive and LUNGevity issue RFA for 2020 ALK-positive Lung Cancer Research Award Program
ALK Positive/LUNGevity is requesting applications for the 2020 ALK-positive Lung Cancer Research Award. Letters of intent are due Feb. 14.
Trials & Tribulations
Advancing the science of cancer in Latinos
Having cancer as a Latino in the United States has important implications potentially related to risk of carcinogenesis, knowledge of cancer prevention, access to cancer screening, therapy timing and choices, and access to good supportive/palliative or survivorship care.
Clinical Roundup
- Keytruda shows mixed results in late-stage lung cancer study
- Breast density notification laws not effective for all women
- Researchers surprised by high levels of alcohol consumption among cancer survivors
- Surgery may add months or years of survival for adults with high-grade gliomas
Drugs & Targets
- FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
- FDA approves Ayvakit for unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor
- Enfortumab vedotin gets FDA accelerated approval for advanced urothelial or bladder cancer
- FDA grants IceCure clearance for expanded indications of cryoablation technology and regulatory approval of MultiSense system
- Canada approves treatment for relapsed/refractory chronic lymphocytic leukemia as part of Project Orbis collaboration

Page 13 of 113« First «...9 10 11 121314 15 16 17 18...30 40 50 60 70 80 90 100 110...»Last »